These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
5. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? Ahmed MH J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417 [TBL] [Abstract][Full Text] [Related]
6. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J; Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108 [TBL] [Abstract][Full Text] [Related]
9. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients. Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597 [TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251 [TBL] [Abstract][Full Text] [Related]
11. Hyperlipidemia of chronic renal failure. Kaysen GA Blood Purif; 1994; 12(1):60-7. PubMed ID: 7986478 [TBL] [Abstract][Full Text] [Related]
12. Practical management of dyslipidemia with elevated lipoprotein(a). Riche DM; East HE; Priest HM J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811 [TBL] [Abstract][Full Text] [Related]
13. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic therapy of lipid disorders in the elderly. Aronow WS Am J Geriatr Cardiol; 2002; 11(4):247-56. PubMed ID: 12091773 [TBL] [Abstract][Full Text] [Related]
15. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Wiklund O; Pirazzi C; Romeo S Curr Cardiol Rep; 2013 Sep; 15(9):397. PubMed ID: 23888382 [TBL] [Abstract][Full Text] [Related]
16. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003 [TBL] [Abstract][Full Text] [Related]
17. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Andersson C; Lyass A; Vasan RS; Massaro JM; D'Agostino RB; Robins SJ Am Heart J; 2014 Dec; 168(6):878-83.e1. PubMed ID: 25458651 [TBL] [Abstract][Full Text] [Related]
18. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Toth PP; Zarotsky V; Sullivan JM; Laitinen D Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901 [TBL] [Abstract][Full Text] [Related]
19. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721 [TBL] [Abstract][Full Text] [Related]
20. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]